Blockchain Registration Transaction Record

Sigyn's CardioDialysis™ Targets 20-Fold Higher Heart Risk in Dialysis Patients

Sigyn Therapeutics' CardioDialysis™ addresses 20-fold higher cardiovascular risk in dialysis patients, leveraging existing dialysis infrastructure to target inflammation and cholesterol during treatments.

This development matters because cardiovascular disease represents the leading cause of death for end-stage renal disease patients, who face dramatically higher mortality rates than the general population despite regular dialysis treatments. Current pharmaceutical approaches have proven ineffective for this vulnerable group, creating an urgent unmet medical need affecting approximately 550,000 ESRD patients in the U.S. alone who undergo 85 million dialysis treatments annually. CardioDialysis™ offers a novel approach that could potentially extend patient survival beyond the current 3-5 year median while addressing the systemic inflammation that dialysis treatments themselves can exacerbate. The technology's ability to leverage existing dialysis infrastructure makes it potentially scalable and accessible, unlike current specialized apheresis treatments available at fewer than 60 centers nationwide. Beyond patient health benefits, successful implementation could transform the economics of dialysis care by reducing hospitalizations and creating new revenue streams in a $100+ billion cardiovascular therapy market.